Vitamin D and Breast Cancer Biomarkers
Vitamin D and Breast Cancer Biomarkers
RATIONALE: Vitamin D may help prevent breast cancer.
PURPOSE: This randomized clinical trial is studying vitamin D and breast cancer biomarkers in female patients.
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a multicenter study. Patients are stratified according to baseline vitamin D (sufficient [≥ 30 ng/mL or ≥ 75 mmol/L] vs insufficient [< 30 ng/mL or < 75 mmol/L]) and institutional random periareolar fine-needle aspiration (RPFNA) status (performs RPFNA vs does not perform RPFNA). Patients are randomized to 1 of 2 treatment arms.
Premenopausal women 55 years of age or younger with regular menstrual cycles (at least four cycles in the last six months). Women with fewer than 4 menses in the last 6 months or who have had a hysterectomy with ovaries intact will be considered premenopausal if FSH level < 20.
Women with breast density ≥ 25% (scattered fibroglandular densities or greater) are eligible.
Prior Treatment
Patients who are currently receiving hormone replacement therapy (estrogen or progesterone); or are taking tamoxifen or raloxifene are not eligible. Women who have taken these medications must have stopped for at least 4 months prior to study entry.
Topical estrogen (eg, transdermal patches and vaginal estrogens) is allowed.
Patients who are currently using hormonal contraception, should be taking it for at least 4 months prior to study entry.
Vitamin D Use
Patients with a history of breast cancer (including DCIS) or ovarian cancer are not eligible.
Patients with a history of breast implants or breast reduction are not eligible.
Patients with two or more bone fractures in the past five years are not eligible.
Patients with a diagnosis of osteoporosis with physician recommendation for treatment of low bone mass are not eligible.
Patients known to have hyperparathyroid disease or other serious disturbances of calcium metabolism requiring intervention in the past 5 years are not eligible.
Patients with a history of kidney stones (unless documented not to have been a calcium stone) are not eligible.
Patients participating in a concurrent breast cancer chemoprevention trial are not eligible.
Required initial laboratory values - Calcium < 10.5 mg/dL
Fort Lauderdale, Florida 33308, United States
Orlando, Florida 32803-1273, United States
Ottawa, Illinois 61350, United States
Peoria, Illinois 61615, United States
La Porte, Indiana 46350, United States
Boston, Massachusetts 02115, United States
South Weymouth, Massachusetts 02190, United States
Columbia, Missouri 65203, United States
Concord, New Hampshire 03301, United States
Lebanon, New Hampshire 03756-0002, United States
East Syracuse, New York 13057, United States
Charlotte, North Carolina 28233-3549, United States
Wilmington, North Carolina 28401, United States
Winston-Salem, North Carolina 27103, United States
Columbus, Ohio 43210-1240, United States
Kingsport, Tennessee 37662, United States